Identification of side population cells in human lung adenocarcinoma A549 cell line and elucidation of the underlying roles in lung cancer

Xie, Tong; Mo, Lingzhao; Li, Li; Mao, Naiquan; Li, Danrong; Liu, De-seng; Chen, Zuo; Huang, Daixin; Pan, Qi; Li, Yang; Wang, Shoufeng

doi:10.3892/ol.2018.7956

Cited by 7 publications

(8 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The enriched SP cells in several lung cancer cell lines (H460, H23, HTB-58, A549, H441, and H2170) showed high tumor-initiating properties, as well as elevated expression of the ABCG2 and ABC transporters that were insensitive to several chemotherapeutics [ 57 ]. The FACS-sorted SP cells from the A549 lung cancer cell line demonstrated increased colony-forming ability [ 58 ] and cell invasiveness, including high tumorigenic potential [ 59 ]. In another study, A549-enriched SP cells, when treated with doxorubicin (DOX) and methotrexate (MTX) manifested active regeneration and high anti-apoptotic abilities [ 60 ].…”

Section: Identification Of Cscs In Lung Cancermentioning

confidence: 99%

Impact of Cancer Stem Cells and Cancer Stem Cell-Driven Drug Resiliency in Lung Tumor: Options in Sight

Cortes-Dericks

Galetta

2022

Cancers

View full text Add to dashboard Cite

Causing a high mortality rate worldwide, lung cancer remains an incurable malignancy resistant to conventional therapy. Despite the discovery of specific molecular targets and new treatment strategies, there remains a pressing need to develop more efficient therapy to further improve the management of this disease. Cancer stem cells (CSCs) are considered the root of sustained tumor growth. This consensus corroborates the CSC model asserting that a distinct subpopulation of malignant cells within a tumor drives and maintains tumor progression with high heterogeneity. Besides being highly tumorigenic, CSCs are highly refractory to standard drugs; therefore, cancer treatment should be focused on eliminating these cells. Herein, we present the current knowledge of the existence of CSCs, CSC-associated mechanisms of chemoresistance, the ability of CSCs to evade immune surveillance, and potential CSC inhibitors in lung cancer, to provide a wider insight to drive a more efficient elimination of this pro-oncogenic and treatment-resistant cell fraction.

show abstract

Section: Identification Of Cscs In Lung Cancermentioning

confidence: 99%

Impact of Cancer Stem Cells and Cancer Stem Cell-Driven Drug Resiliency in Lung Tumor: Options in Sight

Cortes-Dericks

Galetta

2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Many chemotherapeutics are known to be ABCG2 substrates, such as mitoxantrone, methotrexate, doxorubicin, diflomotecan, topotecan, and SN-38 (an active metabolite of irinotecan; Erdei et al, 2018;Hira & Terada, 2018). ABCG2 activity is linked to chemoresistance in various cancers, including ovarian cancer , pancreatic cancer (Stern et al, 2018), lung (Xie et al, 2018) and bladder cancer (Roh et al, 2018). CCN family member 2 (CCN2) (also known as connective tissue growth factor [CTGF]) acts as a multifunctional signaling modulator in various biologic or pathologic processes (Luft, 2008).…”

Section: Introductionmentioning

confidence: 99%

“…Many chemotherapeutics are known to be ABCG2 substrates, such as mitoxantrone, methotrexate, doxorubicin, diflomotecan, topotecan, and SN-38 (an active metabolite of irinotecan; Erdei et al, 2018;Hira & Terada, 2018). ABCG2 activity is linked to chemoresistance in various cancers, including ovarian cancer (Zhang et al, 2018), pancreatic cancer (Stern et al, 2018), lung (Xie et al, 2018) and bladder cancer (Roh et al, 2018).…”

Section: Introductionmentioning

confidence: 99%

CCN2 promotes drug resistance in osteosarcoma by enhancing ABCG2 expression

Tsai

Chang

Tsai

et al. 2018

Journal Cellular Physiology

View full text Add to dashboard Cite

In recent years, osteosarcoma survival rates have failed to improve significantly with conventional treatment modalities because of the development of chemotherapeutic resistance. The human breast cancer resistance protein/ATP binding cassette subfamily G member 2 (BCRP/ABCG2), a member of the ATP‐binding cassette family, uses ATP hydrolysis to expel xenobiotics and chemotherapeutics from cells. CCN family member 2 (CCN2) is a secreted protein that modulates the biological function of cancer cells, enhanced ABCG2 protein expression and activation in this study via the α6β1 integrin receptor and increased osteosarcoma cell viability. CCN2 treatment downregulated miR‐519d expression, which promoted ABCG2 expression. In a mouse xenograft model, knockdown of CCN2 expression increased the therapeutic effect of doxorubicin, which was reversed by ABCG2 overexpression. Our data show that CCN2 increases ABCG2 expression and promotes drug resistance through the α6β1 integrin receptor, whereas CCN2 downregulates miR‐519d. CCN2 inhibition may represent a new therapeutic concept in osteosarcoma.

show abstract

“…Notably, the ABCB1 and ABCG2 transporters are correlated with multidrug chemoresistance by exporting a panel of chemotherapeutic agents, such as paclitaxel, cisplatin, and doxorubicin out of the cell [ 57 , 58 , 59 , 60 ]. It should be noted that even though SP is highly enriched for cells sharing common CSC-related features, such as self-renewal, multipotency, and tumorigenicity, the two populations are not always entirely identical [ 61 , 62 ].…”

Section: Cancer Stem Cells (Cscs)mentioning

confidence: 99%

The Concept of Cancer Stem Cells: Elaborating on ALDH1B1 as an Emerging Marker of Cancer Progression

Tsochantaridis

Roupas

Mohlin

et al. 2023

Life

View full text Add to dashboard Cite

Cancer is a multifactorial, complex disease exhibiting extraordinary phenotypic plasticity and diversity. One of the greatest challenges in cancer treatment is intratumoral heterogeneity, which obstructs the efficient eradication of the tumor. Tumor heterogeneity is often associated with the presence of cancer stem cells (CSCs), a cancer cell sub-population possessing a panel of stem-like properties, such as a self-renewal ability and multipotency potential. CSCs are associated with enhanced chemoresistance due to the enhanced efflux of chemotherapeutic agents and the existence of powerful antioxidant and DNA damage repair mechanisms. The distinctive characteristics of CSCs make them ideal targets for clinical therapeutic approaches, and the identification of efficient and specific CSCs biomarkers is of utmost importance. Aldehyde dehydrogenases (ALDHs) comprise a wide superfamily of metabolic enzymes that, over the last years, have gained increasing attention due to their association with stem-related features in a wide panel of hematopoietic malignancies and solid cancers. Aldehyde dehydrogenase 1B1 (ALDH1B1) is an isoform that has been characterized as a marker of colon cancer progression, while various studies suggest its importance in additional malignancies. Here, we review the basic concepts related to CSCs and discuss the potential role of ALDH1B1 in cancer development and its contribution to the CSC phenotype.

show abstract

Identification of side population cells in human lung adenocarcinoma A549 cell line and elucidation of the underlying roles in lung cancer

Abstract: Abstract. The present study aimed to isolate and characterize side population (SP)

Cited by 7 publications

References 32 publications

Impact of Cancer Stem Cells and Cancer Stem Cell-Driven Drug Resiliency in Lung Tumor: Options in Sight

Impact of Cancer Stem Cells and Cancer Stem Cell-Driven Drug Resiliency in Lung Tumor: Options in Sight

CCN2 promotes drug resistance in osteosarcoma by enhancing ABCG2 expression

The Concept of Cancer Stem Cells: Elaborating on ALDH1B1 as an Emerging Marker of Cancer Progression

Contact Info

Product

Resources

About